Hyperkalaemia

Drug manufacturing
#AstraZeneca #England #Hyperkalaemia #Wales

Access to hyperkalaemia drug expands across England and Wales 

Access to AstraZeneca’s hyperkalaemia treatment Lokelma has been expanded across England and Wales.  AstraZeneca announced the National Institute for Health and Care Excellence (NICE) had issued a draft recommendation for lokelma (sodium zirconium cyclosilicate). Under the new willingness-to-pay threshold, more than double the number of patients could… Read More

#News #Regulatory

NHS Scotland A&E department
#AstraZeneca #Hyperkalaemia #Lokelma #NHS Scotland #Scottish Medicines Consortium (SMC)

Lokelma now available in emergency setting in Scotland

The Scottish Medicines Consortium (SMC) has updated its advice for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate [SZC]) for adult patients with hyperkalaemia in Scotland.   Patients can now access SZC in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care.  SZC is… Read More

#News #Regulatory